Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Price Target at $77.71

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) has been given a consensus rating of "Buy" by the eight brokerages that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $77.71.

Several research analysts have recently commented on the company. HC Wainwright reiterated a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Truist Financial lifted their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a research report on Tuesday, October 22nd. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 price objective on the stock. Piper Sandler began coverage on shares of ANI Pharmaceuticals in a report on Friday, October 11th. They set an "overweight" rating and a $68.00 target price for the company. Finally, Leerink Partnrs raised shares of ANI Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, December 11th.

ANI Pharmaceuticals Stock Down 0.0 %

ANIP traded down $0.02 during trading on Tuesday, reaching $58.44. 79,826 shares of the stock were exchanged, compared to its average volume of 207,403. The stock has a market cap of $1.23 billion, a P/E ratio of -106.26 and a beta of 0.73. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The stock's 50 day moving average price is $56.30 and its two-hundred day moving average price is $58.78. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $148.30 million for the quarter, compared to analysts' expectations of $144.37 million. During the same period in the prior year, the firm earned $1.05 EPS. ANI Pharmaceuticals's quarterly revenue was up 12.5% compared to the same quarter last year. Equities analysts expect that ANI Pharmaceuticals will post 3.86 EPS for the current year.

Insider Buying and Selling

In other news, CFO Stephen P. Carey sold 7,500 shares of the business's stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the transaction, the chief financial officer now directly owns 154,468 shares in the company, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the sale, the senior vice president now owns 49,059 shares in the company, valued at $2,943,540. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,381 shares of company stock valued at $2,441,556 over the last 90 days. 12.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ANIP. JPMorgan Chase & Co. raised its holdings in shares of ANI Pharmaceuticals by 159.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock worth $33,101,000 after buying an additional 340,854 shares in the last quarter. Global Alpha Capital Management Ltd. raised its stake in ANI Pharmaceuticals by 1.8% during the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company's stock worth $32,005,000 after acquiring an additional 9,500 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new position in shares of ANI Pharmaceuticals in the second quarter worth about $228,000. Thompson Siegel & Walmsley LLC boosted its stake in shares of ANI Pharmaceuticals by 17.6% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company's stock valued at $13,731,000 after purchasing an additional 34,416 shares in the last quarter. Finally, Thrivent Financial for Lutherans grew its holdings in shares of ANI Pharmaceuticals by 2.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company's stock valued at $777,000 after purchasing an additional 299 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.